Market Cap 1.47B
Revenue (ttm) 43.27M
Net Income (ttm) -130.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -302.45%
Debt to Equity Ratio 0.00
Volume 1,429,818
Avg Vol 1,347,702
Day's Range N/A - N/A
Shares Out 82.79M
Stochastic %K 98%
Beta 1.67
Analysts Strong Sell
Price Target $34.00

Company Profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clin...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 926 5000
Fax: 617 926 5050
Address:
480 Pleasant Street, Suite C-400, Watertown, United States
rizzato
rizzato Mar. 14 at 3:52 AM
$EYPT https://www.marketbeat.com/instant-alerts/eyepoint-pharmaceuticals-nasdaqeypt-shares-down-91-heres-why-2026-03-12/#google_vignette
0 · Reply
rizzato
rizzato Mar. 14 at 3:39 AM
$EYPT https://altindex.com/ticker/eypt/technical-analysis
0 · Reply
rizzato
rizzato Mar. 14 at 3:36 AM
$EYPT https://tickernerd.com/stock/eypt-forecast/
0 · Reply
rizzato
rizzato Mar. 14 at 3:31 AM
$EYPT https://www.directorstalkinterviews.com/eyepoint-inc-eypt-stock-analysis-a-biotech-with-166-upside-potential/4121244530
0 · Reply
brucino
brucino Mar. 12 at 2:45 PM
$EYPT ahi ahi ahi....tante belle parole, na io vedo le quotazioni in pesante ribasso. Speravo si avvicinasse a 20$ , ma questa ennesima maledetta guerra ci sta facendo sprofondare nel baratro 😡
0 · Reply
rizzato
rizzato Mar. 12 at 2:12 PM
$EYPT now as should be all the shorters are back as the mushroom trying to give more fuel on the fire Now for the moment you can be happy but as already said be careful because good news and you will stay on the floor Let’s see
0 · Reply
Poet5
Poet5 Mar. 12 at 2:09 PM
$EYPT https://www.marketbeat.com/instant-alerts/filing-jefferies-financial-group-inc-purchases-shares-of-140000-eyepoint-pharmaceuticals-inc-eypt-2026-03-12/
0 · Reply
rizzato
rizzato Mar. 12 at 1:54 PM
$EYPT I want 20 usd to but for the moment shorters are jocking with us
0 · Reply
lordBrian
lordBrian Mar. 11 at 8:17 PM
$EYPT we want 20!
1 · Reply
rizzato
rizzato Mar. 11 at 7:38 PM
$EYPT AI Overview Yes, institutional shareholders have shown strong interest and increased their positions in EyePoint Pharmaceuticals (EYPT) shares, with institutions holding over 99% of the stock as of early 2026. Recent data indicates significant buying, including new positions from firms like Stempoint Capital and major increases from Walleye Capital and XTX Topco
0 · Reply
Latest News on EYPT
EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript

Mar 4, 2026, 5:12 PM EST - 10 days ago

EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript


EyePoint Appoints Michael Campbell as Chief Commercial Officer

Feb 18, 2026, 7:00 AM EST - 25 days ago

EyePoint Appoints Michael Campbell as Chief Commercial Officer


EyePoint Announces Pricing of Public Offering

Oct 14, 2025, 10:43 PM EDT - 5 months ago

EyePoint Announces Pricing of Public Offering


EyePoint Announces Proposed Public Offering of Common Stock

Oct 14, 2025, 4:35 PM EDT - 5 months ago

EyePoint Announces Proposed Public Offering of Common Stock


EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference


rizzato
rizzato Mar. 14 at 3:52 AM
$EYPT https://www.marketbeat.com/instant-alerts/eyepoint-pharmaceuticals-nasdaqeypt-shares-down-91-heres-why-2026-03-12/#google_vignette
0 · Reply
rizzato
rizzato Mar. 14 at 3:39 AM
$EYPT https://altindex.com/ticker/eypt/technical-analysis
0 · Reply
rizzato
rizzato Mar. 14 at 3:36 AM
$EYPT https://tickernerd.com/stock/eypt-forecast/
0 · Reply
rizzato
rizzato Mar. 14 at 3:31 AM
$EYPT https://www.directorstalkinterviews.com/eyepoint-inc-eypt-stock-analysis-a-biotech-with-166-upside-potential/4121244530
0 · Reply
brucino
brucino Mar. 12 at 2:45 PM
$EYPT ahi ahi ahi....tante belle parole, na io vedo le quotazioni in pesante ribasso. Speravo si avvicinasse a 20$ , ma questa ennesima maledetta guerra ci sta facendo sprofondare nel baratro 😡
0 · Reply
rizzato
rizzato Mar. 12 at 2:12 PM
$EYPT now as should be all the shorters are back as the mushroom trying to give more fuel on the fire Now for the moment you can be happy but as already said be careful because good news and you will stay on the floor Let’s see
0 · Reply
Poet5
Poet5 Mar. 12 at 2:09 PM
$EYPT https://www.marketbeat.com/instant-alerts/filing-jefferies-financial-group-inc-purchases-shares-of-140000-eyepoint-pharmaceuticals-inc-eypt-2026-03-12/
0 · Reply
rizzato
rizzato Mar. 12 at 1:54 PM
$EYPT I want 20 usd to but for the moment shorters are jocking with us
0 · Reply
lordBrian
lordBrian Mar. 11 at 8:17 PM
$EYPT we want 20!
1 · Reply
rizzato
rizzato Mar. 11 at 7:38 PM
$EYPT AI Overview Yes, institutional shareholders have shown strong interest and increased their positions in EyePoint Pharmaceuticals (EYPT) shares, with institutions holding over 99% of the stock as of early 2026. Recent data indicates significant buying, including new positions from firms like Stempoint Capital and major increases from Walleye Capital and XTX Topco
0 · Reply
rizzato
rizzato Mar. 11 at 7:37 PM
$EYPT Key Institutional Activity and Ownership: High Institutional Control: As of early 2026, institutional investors hold roughly 99.41% of EYPT stock. Recent Buying Activity (Q2 2026 - Projected/Recent Data): Walleye Capital LLC: Grew its position by 500.6%, adding 166,243 shares. XTX Topco Ltd: Boosted holdings by 215.4%, adding 94,210 shares. Stempoint Capital LP: Purchased a new position valued at approximately $3.1 million. Corient Private Wealth LLC: Acquired a new position worth $1.2 million. Top Holders: Major institutional holders include Suvretta Capital Management, BlackRock, Inc., Federated Hermes, Inc., Franklin Resources Inc, and Vanguard Group Inc. Inflow vs. Outflow: In the 12 months leading to March 2026, institutional inflows ($445.19M) significantly outweighed outflows ($92.25M), indicating strong net buying. Fintel Fintel +2 The high institutional interest is likely driven by the company's progress with its lead candidate, Duravyu, for retinal
0 · Reply
rizzato
rizzato Mar. 11 at 3:52 PM
$EYPT JpMorgan keep their buy rating and we are down
0 · Reply
rizzato
rizzato Mar. 11 at 2:29 PM
$EYPT target up share price down is there someone who could explain them that is not normal???????
0 · Reply
LaGoodie
LaGoodie Mar. 9 at 7:28 PM
0 · Reply
erevnon
erevnon Mar. 9 at 6:30 PM
Citigroup maintains EyePoint $EYPT at Buy and raises the price target from $31 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Quantumup
Quantumup Mar. 9 at 1:14 PM
Mizuho $EYPT OP$36 $OCUL $REGN RHHBY KOD $SRZN $FDMT Mizuho said—EYPT reported 4Q results last week, with progress continuing for lead asset Duravyu, with (1) top-line P3 study data in wet AMD/wAMD still expected beginning in mid-2026, and (2) first patient dosing achieved in both P3 studies in diabetic macular edema/DME (with readouts expected in 2H27) That said, given recent reporting of first P3 data for competitor Ocular Therapeutix' (OCUL, NC) Axpaxli, investor debates remain highly active regarding potential differentiation between the two assets, and not surprisingly, this was the main focus on EYPT's 4Q call With this in mind, seeing (1) differentiated/improved efficacy and safety, (2) a better P3 trial design, and (3) a more straightforward path to approval and commercial uptake, we continue to believe Duravyu is better-positioned to become the best-in-class TKI-based maintenance therapy for wAMD As such, we stay Outperform-rated on EYPT, and view recent weakness as a buying opportunity
0 · Reply
LaGoodie
LaGoodie Mar. 6 at 5:20 PM
0 · Reply
rizzato
rizzato Mar. 5 at 11:26 PM
$EYPT dRISK is a platform for uncovering changes in risks to publicly-listed companies. For educational purposes only. AI occasionally makes mistakes. if we use AI everywhere that means we are really at the end of the world it could be helpful but not always please
0 · Reply
rizzato
rizzato Mar. 5 at 10:57 PM
$EYPT what is it ? where did you find it?
0 · Reply
d_risk
d_risk Mar. 5 at 9:14 PM
$EYPT - EyePoint Pharmaceuticals Inc - 10K - Updated Risk Factors EYPT’s risks now center on resolving a DOJ False Claims Act/Anti-Kickback probe over past DEXYCU marketing, with a tentative ~$4.9M settlement and binding corporate integrity agreement that could bring heavy compliance costs, operational burdens, potential exclusion from federal programs, follow-on investigations, litigation, reputational damage, and stock pressure if talks fail or terms are breached; added risks also highlight AI‑driven cyber threats, stricter privacy/data transfer rules, reliance on a sole vorolanib supplier amid new China export controls, and uncertainty around unapproved ophthalmic TKIs. #Pharmaceuticals #RegulatoryCompliance #LegalRisk #SupplyChain #Cybersecurity 🟢 Added 🟠 Removed https://d-risk.ai/EYPT/10-K/2026-03-05
1 · Reply
KimboIce
KimboIce Mar. 5 at 6:38 PM
$EYPT I eat volatility for breakfast.
5 · Reply
PStevenson
PStevenson Mar. 5 at 4:50 PM
$OCUL Down in sympathy with $EYPT Still bullish. Expecting $16+ this year.
0 · Reply